The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy
Abstract
BACKGROUND & AIMS The tumour microenvironment (TME) is a crucial mediator of cancer progression and therapeutic outcome. The TME subtype correlates with patient response to immunotherapy in multiple cancers. Most of the previous studies focused on the role of different cellular components in the TME associated with immunotherapy efficacy. However, the specific structure of the TME and its role in immunotherapy efficacy remain largely unknown. METHODS We combined spatial transcriptomics (ST) with single-cell RNA sequencing (scRNA-seq) and multiplexed immunofluorescence of anti-PD-1-treated hepatocellular carcinoma (HCC) patients to reveal specific spatial structures in the TME related to immunotherapy efficacy. RESULTS We revealed the tumour immune barrier (TIB) structure, a spatial niche composed of SPP1+ macrophages and cancer-associated fibroblasts (CAFs) located near the tumour boundary, which is associated with the efficacy of immune checkpoint blockade (ICB) treatment. Furthermore, we dissected ligand‒receptor networks among malignant cells, SPP1+ macrophages, and CAFs; that is, the hypoxic microenvironment promotes SPP1 expression, and SPP1+ macrophages interact with CAFs to stimulate extracellular matrix remodelling and promote TIB structure formation, thereby limiting immune infiltration in the tumour core. Preclinically, the blockade of SPP1 or macrophage-specific deletion of Spp1 in mice led to enhanced efficacy of anti-PD-1 treatment in mouse liver cancer accompanied by reduced CAF infiltration and increased cytotoxic T-cell infiltration. CONCLUSIONS We identified that the TIB structure formed by the interaction of SPP1+ macrophages and CAFs is related to immunotherapy efficacy. Therefore, disruption of the TIB structure by blocking SPP1 may be considered a relevant therapeutic approach to enhance the therapeutic effect of ICB treatment in HCC. IMPACT AND IMPLICATIONS Only a limited number of patients with HCC benefit from tumour immunotherapy, which significantly hinders the application of immunotherapy in HCC patients. Here, we used multiomics to identify the spatial structure of the tumour immune barrier (TIB), which is formed by the interaction of SPP1+ macrophages and CAFs in the HCC microenvironment and contributes to immunotherapy efficacy by limiting immune cell infiltration into malignant regions. Preclinically, we revealed that blocking SPP1 or macrophage-specific deletion of Spp1 in mice could destroy the TIB structure and sensitize HCC cells to immunotherapy. These results provide the first key steps towards finding more effective therapies for HCC and have a strong impact on physicians, scientists, and drug developers in the field of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
NicheNet: Modeling intercellular communication by linking ligands to target genes
Browaeys, R., Saelens, W., & Saeys, Y. (2020) · Nature Methods · doi:10.1038/s41592-019-0667-5 · Cited by 2,192
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Self-citationCheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Cited by
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Self-citationZhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Fibroblasts in liver cancer: functions and therapeutic translation
Affo, S., Filliol, A., Gores, G. J., & Schwabe, R. F. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00111-5 · Cited by 49
Gao, R., Yuan, X., Ma, Y., Wei, T., Johnston, L., Shao, Y., Lv, W., Zhu, T., Zhang, Y., Zheng, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101536 · Cited by 45
Metadata
- Authors
- Liu, Y., Xun, Z., Ma, K., Liang, S., Li, X., Zhou, S., Sun, L., Liu, Y., Du, Y., Guo, X., Cui, T., Zhou, H., Wang, J., Yin, D., Song, R., Zhang, S., Cai, W., Meng, F., Guo, H., Zhang, B., Yang, D., Bao, R., Hu, Q., Wang, J., Ye, Y., & Liu, L.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2023-04
- Volume
- 78
- Issue
- 4
- Pages
- 770-782
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4318197608
- Cited by
- 735
- References
- 36
- FWCI
- 76.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. https://app.cochat.ai/papers/10.1016/j.jhep.2023.01.011
- The paper
- Liu, Y., Xun, Z., Ma, K., Liang, S., Li, X., Zhou, S., Sun, L., Liu, Y., Du, Y., Guo, X., Cui, T., Zhou, H., Wang, J., Yin, D., Song, R., Zhang, S., Cai, W., Meng, F., Guo, H., . . . Liu, L. (2023). Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2023.01.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.